Breaking News Instant updates and real-time market news.

BLRX

BioLineRx

$2.38

-0.23 (-8.81%)

, BD

Budget Group

$0.00

(0.00%)

04:55
12/14/19
12/14
04:55
12/14/19
04:55

European Society for Medical Oncology to hold a conference

ESMO Immuno-Oncology Congress 2019 will be held in Geneva, Switzerland on December 11-14.

BLRX

BioLineRx

$2.38

-0.23 (-8.81%)

BD

Budget Group

$0.00

(0.00%)

IDRA

Idera Pharmaceuticals

$1.59

-0.05 (-3.05%)

MRK

Merck

$89.18

0.84 (0.95%)

PFE

Pfizer

$38.31

-0.23 (-0.60%)

NKTR

Nektar

$21.28

-0.53 (-2.43%)

  • 17

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

BLRX BioLineRx
$2.38

-0.23 (-8.81%)

05/14/19
HCWC
05/14/19
NO CHANGE
HCWC
BioLineRx has multiple catalysts coming in 2019, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $3 price target on BioLineRx (BLRX) after the company reported in-line Q1 results, with the analyst seeing BL-8040 continuing to deliver positive data on multiple clinical fronts. Pantginis sees "multiple catalysts across all the ongoing programs" for BioLineRx in 2019 that could end the continuing suffering of the shares, including top-line results in the second half of the year from the "Phase 2 triple combo pancreatic cancer trial of BL-8040, Keytruda and chemotherapy under the company's collaboration with Merck (MRK)."
BD Budget Group
$0.00

(0.00%)

IDRA Idera Pharmaceuticals
$1.59

-0.05 (-3.05%)

03/08/19
HCWC
03/08/19
NO CHANGE
Target $14
HCWC
Buy
Idera Pharmaceuticals price target lowered to $14 from $18 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth lowered his price target for Idera Pharmaceuticals to $14 following this week's Q4 results and corporate update. The new target reflects additional dilution from the stock purchase agreement. The analyst keeps a Buy rating on the shares.
03/07/19
WEDB
03/07/19
NO CHANGE
Target $7
WEDB
Outperform
Idera Pharmaceuticals price target lowered to $7 from $16 at Wedbush
Wedbush analyst Robert Driscoll lowered his price target for Idera Pharmaceuticals to $7 from $16 after he tweaked his market assumptions for tilosotolimod in refractory melanoma to be more conservative as the landscape evolves. The analyst continues to see tilsotolimod as a differentiated I-O asset that is being developed in a rational I-O clinical strategy, and reiterates an Outperform rating on the shares.
12/17/18
WEDB
12/17/18
NO CHANGE
Target $16
WEDB
Outperform
Wedbush 'positive' on Idera's Phase 2 study data
Wedbush analyst Robert Driscoll reiterated an Outperform rating and $16 price target on Idera Pharmaceuticals after the company updated results from the ongoing Phase 2 study of tilsotolimod plus ipilumumab in patients with PD-1 refractory melanoma. In a research note to investors, Driscoll says he remains "positive" on the study data, which he believe supports the ongoing Phase 3, and adds that ORR has tracked slightly lower than the previous data cut, but he believes 29.4% remains clinically meaningful with the potential to improve as tumor reductions continue to evolve over time.
MRK Merck
$89.18

0.84 (0.95%)

12/10/19
HCWC
12/10/19
DOWNGRADE
Target $20
HCWC
Neutral
ArQule downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White downgraded ArQule (ARQL) to Neutral from Buy with a price target of $20, up from $13. The analyst cites the proposed takeover by Merck (MRK) for the downgrade.
12/10/19
CANT
12/10/19
DOWNGRADE
Target $20
CANT
Neutral
ArQule downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Varun Kumar downgraded ArQule (ARQL) to Neutral from Overweight with a price target of $20, up from $16. Although other bidders may emerge, the proposed acquisition value paid by Merck (MRK) is fair and makes a "great strategic fit for both parties," Kumar tells investors in a research note.
12/10/19
ROTH
12/10/19
DOWNGRADE
Target $18
ROTH
Neutral
ArQule downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Tony Butler downgraded ArQule (ARQL) to Neutral from Buy with a price target of $18, down from $20, after the company agreed to be acquired by Merck (MRK) for $20 per share in cash for a total equity value of approximately $2.7B. Butler tells investors in a research note that he believes with ArQule's non-covalent BTK inhibitor ARQ 531, Merck may be able to strategically diversify its product portfolio and have an increasing presence in hematologic malignancies.
12/12/19
STFL
12/12/19
NO CHANGE
Target $17
STFL
Buy
Stifel says TherapeuticsMD's Annovera 'insulated' against generic NuvaRing
After Amneal Pharmaceuticals (AMRX) announced this morning that it has received approval from the FDA to market EluRyng, the first generic version of Merck's (MRK) NuvaRing Stifel analyst Annabel Samimy said the new contraceptive vaginal ring entrant may pose a threat to NuvaRing, but she believes TherapeuticsMD's (TXMD) competitor in the class, Annovera, is "insulated" by key product profile distinctions. Samimy points to Annovera's differentiated progesterone and long-acting system to support her view that Annovera successful early launch should shielded from disruption. She maintains a Buy rating and $17 price target on TherapeuticsMD shares.
PFE Pfizer
$38.31

-0.23 (-0.60%)

11/12/19
PIPR
11/12/19
NO CHANGE
Target $185
PIPR
Overweight
Time to dismiss Solid Biosciences as Sarepta competitor, says Piper Jaffray
Piper Jaffray analyst Danielle Brill says that while she had dismissed Solid Biosciences' (SLDB) microdystophin gene therapy program as a competitive threat to Sarepta Therapeutics (SRPT), some investors worried that Solid could provide compelling data after adjusting protocol and moving up the dose. However, today's report of another clinical hold confirms that Solid's construct is toxic, indicating that Pfizer's (PFE) may to too, Brill tells investors in a research note. The analyst points out that both Solid and Pfizer use AAV9 and have had complement mediated serious adverse events after dosing just a few patients. Solid's program reaffirms her view that Sarepta's safety profile is differentiated. It is unlikely that the competition "is viable, let alone will ever catch up," says Brill. She keeps an Overweight rating on Sarepta Therapeutics with a $185 price target. The stock in midday trading is up 4% to $99.02 while Solid Biosciences is down 71% to $3.22.
11/25/19
PIPR
11/25/19
INITIATION
Target $2.5
PIPR
Overweight
Opko Health initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff initiated coverage of Opko Health (OPK) with an Overweight rating and $2.50 price target. The company's partner Pfizer (PFE) recently reported positive Phase III data on once-weekly somatrogo in pediatric growth hormone deficiency, Tenthoff tells investors in a research note. The analyst is confident in the drug and notes that Opko is eligible for up to $275M in milestones plus gross profit share on Genotropin and somatrogon revenue.
11/06/19
PIPR
11/06/19
NO CHANGE
Target $70
PIPR
Neutral
Ionis Pharmaceuticals price target lowered to $70 from $75 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren lowered his price target on Ionis Pharmaceuticals (IONS) to $70 and kept his Neutral rating after its Q3 results, saying that while the quarter was "strong" thanks to the recent $250M upfront payment from Pfizer (PFE), results for its Tegsedi were "uninspiring". The analyst states that an acceleration in Tegsedi is needed soon for him to become more positive on the name ahead of the "potential Phase I/II OLE +natural history Huntington's study readouts next year."
11/01/19
RAJA
11/01/19
UPGRADE
Target $24
RAJA
Outperform
Intellia Therapeutics upgraded to Outperform at Raymond James
Raymond James analyst Steven Seedhouse upgraded Intellia Therapeutics to Outperform from Market Perform with a $24 price target. In a research note to investors, Seedhouse says Intellia's NTLA-2001 is poised to benefit from the "heavy lifting" Pfizer (PFE) is doing commercially with Vyndaqel in ATTR-cardiomyopathy, adding that Intellia is also advancing manufacturing related activities in support of a Phase 1 trial for engineered cell program WT1-TCR in AML. The analyst also says Intellia's lead gene editing program, NTLA-2001 has "really good" primate data showing TTR knockdown potentially better than Alnylam's (ALNY) patisiran. He expects the market will already start to impute downstream clinical benefit for NTLA-2001 after only a few patients with initial TTR knockdown data, because of the collective data for Ionis Pharmaceuticals' (IONS) inotersen and Alnylam's patisiran showing knockdown is relevant.
NKTR Nektar
$21.28

-0.53 (-2.43%)

11/11/19
JPMS
11/11/19
NO CHANGE
JPMS
Neutral
Nektar melanoma data should be well received, says JPMorgan
JPMorgan analyst Jessica Fye expects this weekend's updated results from Nektar Therapeutics's PIVOT-02 melanoma cohort should be well received by investors. While objective response rate and complete responses rates are unchanged since ASCO when median follow-up was 12.7 months, complete responses still has not been reached with median progression-free survival now 18.6 months, Fye tells investors in a research note. The analyst sees the building progression-free survival durability in PIVOT-02 as encouraging, and assumes a 65% probability of success. However, she keeps a Neutral rating on Nektar shares, citing difficulty in identifying a "meaningful near-term catalyst to reverse sentiment."
11/11/19
HCWC
11/11/19
NO CHANGE
Target $32
HCWC
Neutral
Nektar price target raised to $32 from $24 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay raised his price target for Nektar Therapeutics to $32 from $24 while maintaining a Neutral rating on the shares. Durability in frontline melanoma is reassuring following this weekend's data, says Chattopadhyay, who notes he remains "wary." Reasons to be cautious on the new data include the sample size of 41, of which three have been excluded from analysis for a variety of reasons as disclosed previously, and patients having healthier baseline characteristics than historical studies, Chattopadhyay tells investors in a research note.
11/12/19
ADAM
11/12/19
NO CHANGE
Target $24
ADAM
Buy
Nektar price target raised to $24 from $20 at Canaccord
Canaccord analyst Arlinda Lee raised his price target on Nektar to $24 from $20 following its positive presentation of its Phase 1 PIVOT-2 update. The analyst said the increase reflects its increased melanoma prospects and success probability. Lee reiterated her Buy rating on Nektar shares.
11/11/19
HCWC
11/11/19
NO CHANGE
Target $30
HCWC
Buy
Synthorx drug may be safer alternative to Nektar's, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay says Synthorx's (THOR) THOR-707 is "creeping up" on Nektar Therapeutics' (NKTR) bempeg. With THOR-707's profile, the analyst anticipates "profound changes to the pre- and post-treatment biomarkers" when compared to bempeg. In addition, THOR-809 is "poised to be the safer alternative" when compared to Nektar's NKTR-358, Chattopadhyay tells investors in a research note. THOR-809 is "bestowed with a superior ability" to expand CD4 and CD25 and :markedly less" impact on NK cell proliferation compared to NKTR-358, contends the analyst. Chattopadhyay keeps a Buy rating on Synthorx with a $30 price target.

TODAY'S FREE FLY STORIES

11:10
01/17/20
01/17
11:10
01/17/20
11:10
General news
Today's U.S. reports »

Today's U.S. reports…

STT

State Street

$84.45

3.445 (4.25%)

11:08
01/17/20
01/17
11:08
01/17/20
11:08
Periodicals
State Street held talks to find buyer for Currenex, FT reports »

State Street has held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 31

    Jan

  • 26

    Feb

10:55
01/17/20
01/17
10:55
01/17/20
10:55
General news
U.S. equities are modestly firmer at fresh record highs »

U.S. equities are…

ERIC

Ericsson

$9.01

-0.075 (-0.83%)

10:55
01/17/20
01/17
10:55
01/17/20
10:55
Options
Ericsson put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

10:55
01/17/20
01/17
10:55
01/17/20
10:55
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

JBLU

JetBlue

$19.30

0.28 (1.47%)

10:45
01/17/20
01/17
10:45
01/17/20
10:45
Options
JetBlue call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

10:40
01/17/20
01/17
10:40
01/17/20
10:40
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

ES

Eversource

$87.74

0.01 (0.01%)

, CMS

CMS Energy

$65.28

-0.1 (-0.15%)

10:32
01/17/20
01/17
10:32
01/17/20
10:32
Downgrade
Eversource, CMS Energy, NextEra Energy rating change  »

NextEra, CMS Energy,…

ES

Eversource

$87.74

0.01 (0.01%)

CMS

CMS Energy

$65.28

-0.1 (-0.15%)

NEE

NextEra Energy

$251.86

-0.41 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

  • 30

    Jan

  • 12

    Mar

  • 13

    Mar

TWTR

Twitter

$34.14

-0.05 (-0.15%)

, SNAP

Snap

$19.15

0.9 (4.93%)

10:31
01/17/20
01/17
10:31
01/17/20
10:31
On The Fly
Analysts bullish on Pinterest, Snap as Twitter gets downgraded to Neutral »

Shares of social media…

TWTR

Twitter

$34.14

-0.05 (-0.15%)

SNAP

Snap

$19.15

0.9 (4.93%)

PINS

Pinterest

$23.30

0.34 (1.48%)

FB

Facebook

$221.31

-0.47 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

  • 04

    Feb

  • 06

    Feb

  • 06

    Feb

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

10:30
01/17/20
01/17
10:30
01/17/20
10:30
Options
Busy week for 50 Cent as another massive block of calls is bought »

Busy week for 50 Cent as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLAY

Dave & Buster's

$47.28

5.23 (12.44%)

, KKR

KKR

$31.17

0.67 (2.20%)

10:30
01/17/20
01/17
10:30
01/17/20
10:30
Periodicals
KKR not discussing going hostile on Dave & Buster's, Axios reports »

KKR (KKR) has a…

PLAY

Dave & Buster's

$47.28

5.23 (12.44%)

KKR

KKR

$31.17

0.67 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 31

    Jan

  • 26

    Feb

VWAGY

Volkswagen

$0.00

(0.00%)

10:28
01/17/20
01/17
10:28
01/17/20
10:28
Periodicals
VW set to acquire 20% stake in Chinese battery maker Guoxuan, Reuters reports »

Volkswagen is poised to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIZI

Lizhi

$0.00

(0.00%)

10:26
01/17/20
01/17
10:26
01/17/20
10:26
Syndicate
Lizhi opens at $11.03, IPO priced at $11.00 per share »

Lizhi (LIZI) priced 4.1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Wolfe Research tech strategist to hold an analyst/industry webcast »

Tech Strategist…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
UBS services analysts to hold an analyst/industry conference call »

Services Analyst Lasser,…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Wolfe Research industrials analysts to hold an analyst/industry webcast »

Multi-Idndustry Analyst…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
JPMorgan U.S. telecom & semis analysts hold an analyst/industry conference call »

U.S. Telecom &…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Cowen Washington policy strategist to hold an analyst/industry conference call »

Washington Policy…

MIDD

Middleby

$111.11

1.51 (1.38%)

, MCD

McDonald's

$212.00

1.14 (0.54%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Recommendations
Middleby, McDonald's, Welbilt analyst commentary  »

Middleby equimpment may…

MIDD

Middleby

$111.11

1.51 (1.38%)

MCD

McDonald's

$212.00

1.14 (0.54%)

WBT

Welbilt

$15.39

-0.06 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

CMS

CMS Energy

$65.31

-0.07 (-0.11%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Downgrade
CMS Energy rating change  »

CMS Energy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 12

    Mar

  • 13

    Mar

ES

Eversource

$87.64

-0.09 (-0.10%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Downgrade
Eversource rating change  »

Eversource downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

NEE

NextEra Energy

$252.14

-0.13 (-0.05%)

10:23
01/17/20
01/17
10:23
01/17/20
10:23
Downgrade
NextEra Energy rating change  »

NextEra Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

STT

State Street

$85.19

4.185 (5.17%)

10:22
01/17/20
01/17
10:22
01/17/20
10:22
Hot Stocks
State Street management 'confident in capital position' »

Comment from Q4 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 31

    Jan

  • 26

    Feb

10:20
01/17/20
01/17
10:20
01/17/20
10:20
Conference/Events
Wolfe Research energy analysts to hold an analyst/industry luncheon »

Energy Analysts…

GLD

SPDR Gold Shares

$146.63

0.33 (0.23%)

10:20
01/17/20
01/17
10:20
01/17/20
10:20
Options
Gold ETF call volume surges on March spread »

Gold ETF call volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.